Pfizer Beats First Quarter Profit Estimates on Eliquis
Pfizer reported an adjusted quarterly profit of 75 cents per share, surpassing analyst expectations of 72 cents. The results were driven by strong demand for established drugs including the blood thinner Eliquis.
Xurve View
Insights:
Xurve View
PFIZER INC reported adjusted first-quarter profit of 75 cents per share, beating analyst estimates of 72 cents. The result was driven by sustained demand for established products like the blood thinner Eliquis. Strong performance in legacy drugs provides a buffer as the drugmaker navigates post-pandemic revenue shifts.
